NCT00849394已完成不适用
An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab
North Texas Veterans Healthcare System3 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2007年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 3
- 主要终点
- To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria.
研究概览
简要总结
This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 18 years older
- •Patients must be receiving his/her first dose of bevacizumab
- •Patients must sign an informed consent
排除标准
- •Patients receiving > 10 mg/kg doses of bevacizumab
结局指标
主要结局
To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria.
时间窗: 3-6 months
次要结局
- To evaluate the time (number of days) to the incidence of proteinuria with shortened infusions of bevacizumab AND to evaluate the effect of controlled versus uncontrolled hypertension and the incidence of proteinuria.(3-6 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple MyelomaMultiple MyelomaNCT01572857Rennes University Hospital30
招募中
1 期
Clinical observation on treatment of proteinuria in stage i-ii of chronic kidney disease by acupoint selection based on syndrome differentiation combined with classical prescriptionsITMCTR2100004883Heilongjiangl Academy of Traditional Chinese Medicine
已完成
1 期
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With ProteinuriaProteinuriaNCT05314231Alexion Pharmaceuticals, Inc.13
已完成
不适用
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and ProteinuriaDiabetic Kidney DiseaseProteinuriaHypertension,EssentialNCT05086549Boryung Pharmaceutical Co., Ltd360
Unknown
不适用
Random Urine Protein-creatinin Ratio to Predict Magnitude of ProteinuriaPre-eclampsiaNCT01623791Cukurova University209